ACE2 News and Research

RSS

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

25 Oct 2021

Immune evasion by SARS-CoV-2 facilitated by a mutational hotspot in the NTD

Researchers discuss mutations in the NTD of the spike protein, which contains an antigenic “supersite” and is the target for nAbs.

24 Oct 2021

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

A team of researchers measured the infectivity of SARS-CoV-2 variants C.1.2, Mu, and Delta+501S spike proteins and determined the susceptibility to neutralizing antibodies.

22 Oct 2021

Replication of SARS-CoV-2 variants in different cell and organ models

In this study, the replication of B.1.1.7 viruses was analyzed in different cell and organ models and dwarf hamsters.

22 Oct 2021

Development of a safe and effective COVID-19 nanoparticle vaccine

Researchers from ReVacc scientific have attempted to demonstrate the effectiveness of a new vaccine, REVC-128, two weeks post-administration.

22 Oct 2021

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

Researchers from Stanford University have been attempting to create a hydrogel-based vaccine delivery system that could improve the immune response's strength and duration.

22 Oct 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021

Development of a plant-based platform for the production of SARS-CoV-2 antigen

Scientists have recently focused on the development of plant-based recombinant protein platforms.

21 Oct 2021

New research on phagocytosis and SARS-CoV-2's spike protein

A new study showed that convalescent patient plasma and monoclonal anti-spike antibodies were able to induce phagocytosis at high antibody concentrations.

20 Oct 2021

Biomarker predicts severity of SARS-CoV-2 infection in patients

A new study investigates a biomarker to predict the severity of disease in patients infected with SARS-CoV-2.

20 Oct 2021

The neutralization potential of nanobodies against SARS-CoV-2

A recent review describes the role of nanobodies as a new class of recombinant antibodies that are used in the treatment of COVID-19.

20 Oct 2021

Suggested mechanism of SARS-CoV-2 infection inhibition by Mitoxantrone

A group of researchers performed a drug repurposing screen on an FDA-approved anti-cancer drug named Mitoxantrone.

20 Oct 2021

Safety and oral immunogenicity of a VSV-derived mucosal vaccine against SARS-CoV-2

A team of researchers exploited the known tropism of vesicular stomatitis virus to develop an oral vaccine that expresses the immunogenic SARS-CoV-2 spike glycoprotein in the oral mucosa.

20 Oct 2021

Long-term predictions of immunity after two doses of mRNA vaccine

Researchers from York University has investigated the long-term protection of two mRNA vaccines.

20 Oct 2021

BNT162b2 mRNA COVID-19 vaccine-induced antibodies wane over six month period

Researchers have been investigating the response of antibodies created against SARS-CoV-2 by the Pfizer-BioNTech six months after vaccination.

20 Oct 2021

Research may provide clues to how viral infections contribute to neurodegeneration

Some viral diseases could possibly contribute to neurodegeneration. DZNE researchers report this in the scientific journal "Nature Communications".

19 Oct 2021

Structural mechanism of anti-SARS-CoV-2 neutralizing antibodies that target separate spike epitopes

Researchers from the Washington University School Of Medicine have identified how a subset of variants of concern can escape neutralization by two neutralizing antibodies.

19 Oct 2021

Nasal delivery of single-domain antibodies improves SARS-CoV-2 symptoms in animal model

In a recent study published in the journal PLOS Pathogens, scientists showed that nasal administration of a single-domain antibody (VHH), named K-874A, brought about inhibition of SARS-CoV-2 titers in infected lungs of Syrian hamsters.

19 Oct 2021

SARS-CoV-2 antibodies detected in breast milk of vaccinated mothers

Now, a new medRxiv* preprint study finds mothers vaccinated either one of the messenger RNA (mRNA) vaccines transferred neutralizing antibodies and cytokines, including interferon-gamma (IFNγ), to a breastfeeding child. Additionally, the humoral response in breastmilk was effective in neutralizing four variants of concern.

18 Oct 2021

How can framing COVID-19 vaccine side-effects affect an individual's willingness to be vaccinated?

Researchers from the University of Munich have investigated how framing vaccine side-effects can affect an individual's willingness to be vaccinated.

18 Oct 2021

ACE2 News and Research

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

Immune evasion by SARS-CoV-2 facilitated by a mutational hotspot in the NTD

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

Replication of SARS-CoV-2 variants in different cell and organ models

Development of a safe and effective COVID-19 nanoparticle vaccine

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Development of a plant-based platform for the production of SARS-CoV-2 antigen

New research on phagocytosis and SARS-CoV-2's spike protein

Biomarker predicts severity of SARS-CoV-2 infection in patients

The neutralization potential of nanobodies against SARS-CoV-2

Suggested mechanism of SARS-CoV-2 infection inhibition by Mitoxantrone

Safety and oral immunogenicity of a VSV-derived mucosal vaccine against SARS-CoV-2

Long-term predictions of immunity after two doses of mRNA vaccine

BNT162b2 mRNA COVID-19 vaccine-induced antibodies wane over six month period

Research may provide clues to how viral infections contribute to neurodegeneration

Structural mechanism of anti-SARS-CoV-2 neutralizing antibodies that target separate spike epitopes

Nasal delivery of single-domain antibodies improves SARS-CoV-2 symptoms in animal model

SARS-CoV-2 antibodies detected in breast milk of vaccinated mothers

How can framing COVID-19 vaccine side-effects affect an individual's willingness to be vaccinated?

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News